TSX lower as gold rally takes a breather
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ:NAGE) announced Wednesday that its pharmaceutical-grade Niagen Plus products, including Niagen IV and injections, are now available at more than 50 iCRYO locations across the U.S., bringing total availability to over 900 clinics nationwide. The company’s expansion comes amid impressive financial performance, with InvestingPro data showing a 162% return over the past year and robust revenue growth of 36% in the last twelve months.
The expansion marks a significant distribution milestone for the company’s nicotinamide riboside (NR) products, which are designed to boost levels of NAD+ (nicotinamide adenine dinucleotide), a coenzyme that declines with age and is essential for cellular energy, DNA repair, and metabolism. According to InvestingPro analysis, NAGE maintains strong financial health with a current ratio of 3.88, indicating solid operational efficiency. For deeper insights into NAGE’s financial metrics and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
According to the company, Niagen IV offers advantages over traditional NAD+ IV therapy, including a shorter infusion time of 30-45 minutes compared to several hours for NAD+ IV treatments. A pilot clinical study cited in the announcement indicated that Niagen IV resulted in a 20% increase in whole blood NAD+ levels three hours post-infusion.
"This milestone highlights the growing recognition of Niagen IV and injections as essential tools for supporting healthspan," said Rob Fried, CEO of Niagen Bioscience, in the press release.
The partnership with iCRYO, a wellness franchise with locations across the country, aligns with both companies’ focus on preventative health solutions.
"This collaboration aligns with our mission to elevate the standard of health, wellness, and longevity globally through cutting-edge solutions," said Kyle Jones, CEO and Co-founder of iCRYO.
Niagen Bioscience, formerly known as ChromaDex Corp., positions itself as a leader in NAD+ science and healthy-aging research. The company’s Niagen is marketed as the "most efficient and high-quality NAD+ booster" available both orally as Tru Niagen and intravenously as Niagen Plus.
The announcement comes as interest in NAD+ therapies continues to grow within the wellness and longevity sectors, according to information provided in the company statement.
In other recent news, Niagen Bioscience reported its second-quarter 2025 financial results, surpassing analysts’ expectations. The company achieved earnings per share of $0.04, doubling the anticipated $0.02, and generated revenue of $31.1 million, exceeding projections by 9.66%. Following these strong results, H.C. Wainwright raised its price target for Niagen Bioscience from $11 to $12 while maintaining a Buy rating. These developments highlight Niagen Bioscience’s ability to outperform financial forecasts and have garnered positive attention from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.